An RNA editing fingerprint of cancer stem cell reprogramming

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Crews, Leslie A ^a,b   Jiang, Qingfei ^a,b   Zipeto, Maria A ^a,b   Lazzari, Elisa ^a,b,c   Court, Angela C ^a,b   Ali, Shawn ^a,b   Barrett, Christian L ^d   Frazer, Kelly A ^d   Jamieson, Catriona H M ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADAR1; Biomarkers; Cancer stem cells; Leukemia; Leukemia stem cells; RNA editing

Indexed keywords

PROTEIN MDM2; TRANSCRIPTION FACTOR GLI1; ADENOSINE DEAMINASE; TUMOR MARKER;

3' UNTRANSLATED REGION; APOBEC3D GENE; ARTICLE; AZIN1 GENE; CANCER GROWTH; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOID LEUKEMIA STEM CELL; CONTROLLED STUDY; EXON; GENE; GLI1 GENE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRON; LEUKEMIA CELL LINE; MDM2 GENE; NUCLEAR REPROGRAMMING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EDITING; RNA EDITING SITE SPECIFIC QUANTITATIVE RT PCR; SEQUENCE ANALYSIS; SEQUENCING CHROMATOGRAM ANALYSIS; SITE DIRECTED MUTAGENESIS; STEM CELL; BIOLOGICAL MODEL; BLAST CELL CRISIS; COCULTURE; DISEASE COURSE; GENETICS; K-562 CELL LINE; LENTIVIRINAE; METABOLISM; PATHOLOGY; REPRODUCIBILITY;

ADENOSINE DEAMINASE; BIOMARKERS, TUMOR; BLAST CRISIS; CELLULAR REPROGRAMMING; COCULTURE TECHNIQUES; DISEASE PROGRESSION; HUMANS; K562 CELLS; LENTIVIRUS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; REPRODUCIBILITY OF RESULTS; RNA EDITING;

EID: 84924338558     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0370-3     Document Type: Article

References (44)

1. Jiang Q, Crews LA, Barrett CL, Chun HJ, Court AC, Isquith JM, et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2013;110:1041-6.
2. Ma CH, Chong JH, Guo Y, Zeng HM, Liu SY, Xu LL, et al. Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias. Biochem Biophys Res Commun. 2011;406:245-51.
3. Steinman RA, Yang Q, Gasparetto M, Robinson LJ, Liu X, Lenzner DE, et al. Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice. Int J Cancer. 2013;132:1741-50.
4. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461:809-13.
5. Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med. 2013;19:209-16.
6. Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, et al. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014;63:832-43.
7. Qin YR, Qiao JJ, Chan TH, Zhu YH, Li FF, Liu H, et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res. 2014;74:840-51.
8. Athanasiadis A, Rich A, Maas S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol. 2004;2:e391.
9. Levanon EY, Eisenberg E, Yelin R, Nemzer S, Hallegger M, Shemesh R, et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol. 2004;22:1001-5.
10. Bass BL, Weintraub H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell. 1988;55:1089-98.
11. XuFeng R, Boyer MJ, Shen H, Li Y, Yu H, Gao Y, et al. ADAR1 is required for hematopoietic progenitor cell survival via RNA editing. Proc Natl Acad Sci U S A. 2009;106:17763-8.
12. Wang Q, Khillan J, Gadue P, Nishikura K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science. 2000;290:1765-8.
13. Hartner JC, Walkley CR, Lu J, Orkin SH. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol. 2009;10:109-15.
14. Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010;79:321-49.
15. Solomon O, Oren S, Safran M, Deshet-Unger N, Akiva P, Jacob-Hirsch J, et al. Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR). RNA. 2013;19:591-604.
16. Wang IX, So E, Devlin JL, Zhao Y, Wu M, Cheung VG. ADAR regulates RNA editing, transcript stability, and gene expression. Cell Rep. 2013;5:849-60.
17. Greenberger S, Levanon EY, Paz-Yaacov N, Barzilai A, Safran M, Osenberg S, et al. Consistent levels of A-to-I RNA editing across individuals in coding sequences and non-conserved Alu repeats. BMC Genomics. 2010;11:608.
18. Yang W, Chendrimada TP, Wang Q, Higuchi M, Seeburg PH, Shiekhattar R, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol. 2006;13:13-21.
19. Ramaswami G, Lin W, Piskol R, Tan MH, Davis C, Li JB. Accurate identification of human Alu and non-Alu RNA editing sites. Nat Methods. 2012;9:579-81.
20. Kiran A, Baranov PV. DARNED: a database of RNa editing in humans. Bioinformatics. 2010;26:1772-6.
21. Porath HT, Carmi S, Levanon EY. A genome-wide map of hyper-edited RNA reveals numerous new sites. Nat Commun. 2014;5:4726.
22. Kleinman CL, Majewski J. Comment on "Widespread RNA and DNA sequence differences in the human transcriptome". Science. 2012;335:1302. author reply 1302.
23. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657-67.
24. Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A. 2009;106:3925-9.
25. Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ. Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor. Blood. 1996;88:3765-73.
26. Lai F, Drakas R, Nishikura K. Mutagenic analysis of double-stranded RNA adenosine deaminase, a candidate enzyme for RNA editing of glutamate-gated ion channel transcripts. J Biol Chem. 1995;270:17098-105.
27. Goff DJ, Recart AC, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013;12:316-28.
28. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-22.
29. Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008;13:321-30.
30. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001;29:E88-88.
31. Bahn JH, Lee JH, Li G, Greer C, Peng G, Xiao X. Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res. 2012;22:142-50.
32. Shimokawa T, Rahman MF, Tostar U, Sonkoly E, Stahle M, Pivarcsi A, et al. RNA editing of the GLI1 transcription factor modulates the output of Hedgehog signaling. RNA Biol. 2013;10:321-33.
33. Olsen RR, Zetter BR. Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. Mol Cancer Res. 2011;9:1285-93.
34. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17:2503-16.
35. Zhang R, Li X, Ramaswami G, Smith KS, Turecki G, Montgomery SB, et al. Quantifying RNA allelic ratios by microfluidic multiplex PCR and sequencing. Nat Methods. 2014;11:51-4.
36. Nakae A, Tanaka T, Miyake K, Hase M, Mashimo T. Comparing methods of detection and quantitation of RNA editing of rat glycine receptor alpha3. Int J Biol Sci. 2008;4:397-405.
37. Roberson LM, Rosenthal JJ. An accurate fluorescent assay for quantifying the extent of RNA editing. RNA. 2006;12:1907-12.
38. Chen YC, Kao SC, Chou HC, Lin WH, Wong FH, Chow WY. A real-time PCR method for the quantitative analysis of RNA editing at specific sites. Anal Biochem. 2008;375:46-52.
39. Gommans WM, McCane J, Nacarelli GS, Maas S. A mammalian reporter system for fast and quantitative detection of intracellular A-to-I RNA editing levels. Anal Biochem. 2010;399:230-6.
40. Garncarz W, Tariq A, Handl C, Pusch O, Jantsch MF. A high-throughput screen to identify enhancers of ADAR-mediated RNA-editing. RNA Biol. 2013;10:192-204.
41. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nature genetics. 2013;45:970-6.
42. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979-93.
43. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nature genetics. 2014;46:487-91.
44. Gaisler-Salomon I, Kravitz E, Feiler Y, Safran M, Biegon A, Amariglio N, et al. Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease. Neurobiol Aging. 2014;35:1785-91.